A small Cambridge firm said that Bill Gates of Microsoft fame was among the investors of a seed round of financing.
In a press release, Nimbus Discovery LLC disclosed neither the size of Gates's investment nor the amount of the seed round.
Nimbus describes itself as a biopharmaceutical company that uses "state-of the-art computational technology" to develop new medicines.
The seed round included investments from Gates; Richard Friesner, cofounder of Schrödinger, and Atlas Venture, a venture capital firm with offices in Cambridge, Nimbus said in a press release. Schrödinger is a firm that develops chemical simulation software for pharmaceutical and biotechnology research.
In a statement, Bruce Booth, chairman and cofounder of Nimbus and a Partner at Atlas Venture, said: "I am excited to welcome Bill Gates and Richard Friesner as investors in Nimbus. Their investment recognizes the unique opportunity Nimbus has to leverage Schrödinger's 20-year technology investment with a virtually-integrated, globally distributed R&D approach."
On his blog, Booth expanded on Gates's interest in biotechnology.
Nimbus said it plans to use funds from the seed round to advance its programs in diffuse large B-cell lymphoma, an aggressive blood cancer; inflammatory disorders; and metabolic disease.
In a press release, Nimbus Discovery LLC disclosed neither the size of Gates's investment nor the amount of the seed round.
Nimbus describes itself as a biopharmaceutical company that uses "state-of the-art computational technology" to develop new medicines.
The seed round included investments from Gates; Richard Friesner, cofounder of Schrödinger, and Atlas Venture, a venture capital firm with offices in Cambridge, Nimbus said in a press release. Schrödinger is a firm that develops chemical simulation software for pharmaceutical and biotechnology research.
In a statement, Bruce Booth, chairman and cofounder of Nimbus and a Partner at Atlas Venture, said: "I am excited to welcome Bill Gates and Richard Friesner as investors in Nimbus. Their investment recognizes the unique opportunity Nimbus has to leverage Schrödinger's 20-year technology investment with a virtually-integrated, globally distributed R&D approach."
On his blog, Booth expanded on Gates's interest in biotechnology.
Nimbus said it plans to use funds from the seed round to advance its programs in diffuse large B-cell lymphoma, an aggressive blood cancer; inflammatory disorders; and metabolic disease.
No comments:
Post a Comment